Anticancer effect of crizotinib on osteosarcoma cells by targeting c-Met signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• C-Met receptor and hepatocyte growth factor (HGF) are overexpressed in osteosarcoma, suggesting their role in tumor development.
• Targeting the c-Met/HGF pathway presents a potential therapeutic strategy for osteosarcoma.

Purpose of the Study:

• To investigate the anticancer effects of crizotinib, a c-Met-targeted drug, on osteosarcoma (OS) cells.
• To evaluate crizotinib's impact on OS cell proliferation, apoptosis, cell cycle, migration, and invasion.
• To analyze the effect of crizotinib on the c-Met signaling pathway in OS cells.

Main Methods:

• Osteosarcoma cell lines (SaOS2, MG-63, MNNG) were treated with varying concentrations of crizotinib.
• Cell proliferation was assessed using the CCK8 assay.
• Apoptosis, cell cycle, migration, and invasion were evaluated in MG-63 cells.
• Western blotting was employed to detect c-Met signaling pathway protein expression.

Main Results:

• Crizotinib demonstrated a dose-dependent inhibition of osteosarcoma cell proliferation.
• Crizotinib significantly increased cancer cell apoptosis and altered the cell cycle distribution (increased G0/G1, decreased S phase).
• Crizotinib suppressed osteosarcoma cell migration and invasion, and downregulated the c-Met/Gab1/STAT5 pathway.

Conclusions:

• Crizotinib exhibits significant anticancer activity against osteosarcoma cells in vitro.
• The c-Met signaling pathway is a viable therapeutic target for osteosarcoma treatment.
• Crizotinib shows promise as a potential therapeutic agent for clinical application in osteosarcoma.